FDA approves use of combo for hepatitis C in children

12/14/2008 | Winston-Salem Journal (N.C.)

Schering-Plough obtained FDA clearance to market a regimen that combines Rebetol -- an antiviral drug -- with Pegintron -- a bioengineered version of an immune-system protein called interferon -- to treat hepatitis C in children ages 3 to 17. The two-drug therapy offers extended effectiveness with the aid of pegylation, a technology used in Pegintron that allows it to remain in the blood longer.

View Full Article in:

Winston-Salem Journal (N.C.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX